SPS
FULC icon

Susquehanna Portfolio Strategies’s Fulcrum Therapeutics FULC Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$148K Buy
+19,321
New +$179K ﹤0.01% 920
2024
Q3 		– Sell
-81,217
Closed -$504K – 410
2024
Q2 		$504K Sell
81,217
-87,558
-52% -$663K 0.02% 365
2024
Q1 		$1.59M Hold
168,775
– – 0.04% 368
2023
Q4 		$1.14M Buy
+168,775
New +$749K 0.02% 566

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Susquehanna Portfolio Strategies's FULC Position: Q1 2026 in Review

Susquehanna Portfolio Strategies opened a new position in Fulcrum Therapeutics (FULC) in Q1 2026: 19,321 shares worth $148K. The stake represents ﹤0.01% of the portfolio and ranks #920 among its holdings. This is a return to the name: Susquehanna Portfolio Strategies previously reported a position in FULC as recently as Q2 2024.

Susquehanna Portfolio Strategies first reported a position in FULC in Q4 2023 and has held it in 4 quarters since. The position peaked at $1.59M in Q1 2024. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Susquehanna Portfolio Strategies held 19,321 shares of Fulcrum Therapeutics worth $148K as of Q1 2026.
  • Fulcrum Therapeutics was a new Susquehanna Portfolio Strategies position in Q1 2026.
  • Fulcrum Therapeutics made up ﹤0.01% of Susquehanna Portfolio Strategies's portfolio in Q1 2026, its #920 holding.
  • Susquehanna Portfolio Strategies first reported a position in Fulcrum Therapeutics in Q4 2023 and has held it in 4 quarters since.
  • Susquehanna Portfolio Strategies's Fulcrum Therapeutics position peaked at $1.59M in Q1 2024.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q1 2026, filed 15 May 2026.